Benefits
Hemispheric ischemic stroke (EPICA RCT)
EPICA Trial — randomized double-blind multicenter placebo-controlled trial in 151 patients with hemispheric ischemic stroke. EMHPS administration IMPROVED neurological status vs placebo. Foundational positive RCT supporting Russian regulatory approval. Limited by predominantly Russian conduct/publication.
Chronic brain ischemia (multicenter RCT n=318)
Multicenter randomized double-blind trial in 318 patients with chronic brain ischemia confirmed STATISTICALLY SIGNIFICANT BENEFIT of EMHPS over placebo through basic neurological tests. Larger sample provides strengthened evidence base. Russian clinical literature documents long-term cognitive benefits.
MIR Phase 3 international stroke trial
Prospective international multicenter randomized double-blind placebo-controlled Phase 3 trial of Mexidol sequential therapy in patients in acute and early recovery periods of ischemic stroke. Standard therapy + Mexidol 500 mg 2x daily IV for 10 days then Mexidol FORTE 250 orally 3x daily for 60 days vs placebo. Status: COMPLETED. Demonstrates ongoing pharmaceutical development with international scope. Results integrated into Russian clinical recommendations.
Stroke + thrombolysis combination
Krylov 2012 — comparative efficiency of Mexidol IV combined with thrombolytic therapy in 116 ischemic stroke patients. 46 patients received thrombolysis + mexidol; 70 patients received standard thrombolysis. SYNERGISTIC EFFECT — significantly faster normalization of acute indicators correlating with reduced neurological deficit. Establishes mexidol as adjunct to standard thrombolytic care in Russian clinical practice.
Stroke rehabilitation cognitive recovery
Multiple Russian trials show mexidol in rehabilitation period IMPROVES recovery of neurological functions, regression of neurological deficit and cognitive disorders (memory improvement), reduced asthenic syndrome, increased socio-household adaptation, improved psycho-emotional state, decreased spasticity, increased motor/speech activity, eliminated ignoring syndrome. Multi-domain rehabilitation benefits.
Hyperlipidemia and hypercoagulation effects
Russian post-stroke studies show mexidol DECREASES total cholesterol and low-density β-lipoproteins in blood, reduces severity of hypercoagulation. Cardiovascular and hematological benefits beyond pure neuroprotection. Mechanism: antioxidant effects on lipid metabolism + anti-inflammatory effects on coagulation cascade. Multi-organ benefits explain broad indication base.
Mechanism of action
Antioxidant via free radical scavenging
EMHPS scavenges free radicals (hydroxyl, peroxyl, superoxide). 3-hydroxypyridine moiety provides antioxidant activity. Reduces lipid peroxidation, oxidative damage to proteins, mitochondrial DNA. Mechanism for tissue protection in ischemia and aging.
Mitochondrial succinate delivery (energy metabolism)
Succinate counter-ion provides direct substrate for mitochondrial Complex II (succinate dehydrogenase) — supporting oxidative phosphorylation under hypoxic stress. Mechanism for antihypoxic effects and energy metabolism support. Distinct from typical antioxidants.
Anti-inflammatory effects
Reduces pro-inflammatory cytokine production. Mechanism via free radical reduction and anti-NF-κB effects. Foundation for stroke neuroprotection and broad clinical use.
Membrane-stabilizing effects
Stabilizes neuronal membranes during ischemic stress. Reduces calcium influx and excitotoxic damage. Mechanism for stroke neuroprotection. Distinct from typical lipid-soluble antioxidants.
Anxiolytic (GABA-related)
Mild GABA-related anxiolytic effects beyond antioxidant mechanisms. Used for anxiety in Russian clinical practice. Mechanism less well-characterized than primary antioxidant effects.
Hemorheological effects
Reduces blood viscosity, decreases hematocrit and fibrinogen, increases erythrocyte deformability (Lyusov 2019 PMID 31184628). Mechanism for cerebral microcirculation improvement. Important contribution to stroke benefits.
ABCB1 and SLCO1B1 inhibition
EMHPS inhibits but is NOT substrate of ABCB1 (P-glycoprotein) and SLCO1B1 transporters (PMC10674565). Mechanism for potential drug-drug interactions. CYP3A4 INDUCER property. Important pharmacokinetic considerations for combination therapy.
Clinical trials
Russian multicenter randomized double-blind placebo-controlled trial.
151 patients with hemispheric ischemic stroke. EMHPS (mexidol) administration vs placebo. Neurological status assessed.
EMHPS administration IMPROVED neurological status of patients vs placebo. Statistically significant benefit established. Foundational positive RCT supporting Russian regulatory approval for ischemic stroke. Russian-language publication limits Western evidence assessment.
Prospective international multicenter randomized double-blind placebo-controlled Phase 3 trial (NCT06437626, Pharmasoft sponsor). COMPLETED.
Patients in acute and early recovery periods of ischemic stroke. Standard therapy + Mexidol 500 mg 2x daily IV for 10 days then Mexidol FORTE 250 mg 3x daily orally for 60 days vs placebo + standard therapy. 4-visit assessment design.
Phase 3 trial COMPLETED. Designed to evaluate comparative efficacy and safety of sequential Mexidol therapy. Results pending publication but integrated into Russian clinical recommendations for ischemic stroke and TIA. Demonstrates ongoing rigorous pharmaceutical development with international scope.
Russian comparative effectiveness study (Krylov VV, Petrikov SS, Solodov AA 2012, Zh Nevrol Psikhiatr Im S S Korsakova 112(8 Pt 2):17-21, PMID 22810741).
116 patients with ischemic stroke divided into two groups: thrombolysis + mexidol (n=46) vs thrombolysis + standard therapy (n=70).
SYNERGISTIC EFFECT — combination of thrombolysis with mexidol led to SIGNIFICANTLY FASTER NORMALIZATION of acute indicators, which correlated with degree of reduction of neurological deficit. Establishes mexidol as evidence-based adjunct to thrombolytic care. Important practical clinical evidence supporting Russian routine use.